Paclitaxel Clinical Trials

17 recruitingLast updated: July 25, 2026

There are 17 actively recruiting paclitaxel clinical trials across 9 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include Tianjin, Outside U.S., China, Shijiazhuang, Hebei, China, Avignon, France. Updated daily from ClinicalTrials.gov.


Paclitaxel Trials at a Glance

17 actively recruiting trials for paclitaxel are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Tianjin, Shijiazhuang, and Avignon. Lead sponsors running paclitaxel studies include Tianjin Medical University Second Hospital, Hebei Medical University Fourth Hospital, and Chipscreen Biosciences, Ltd..

Browse paclitaxel trials by phase

Treatments under study

About Paclitaxel Clinical Trials

Looking for clinical trials for Paclitaxel? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Paclitaxel trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Paclitaxel clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 1Phase 2

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Metastatic Appendiceal AdenocarcinomaIntraperitoneal Paclitaxel
M.D. Anderson Cancer Center39 enrolled1 locationNCT06207305
Recruiting

Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer

Gastric CancerChemotherapy Induced Peripheral NeuropathyPaclitaxel+1 more
City of Hope Medical Center150 enrolled1 locationNCT06490159
Recruiting
Phase 2

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study

NSCLCTislelizumabNab-paclitaxel+1 more
Qilu Hospital of Shandong University34 enrolled1 locationNCT07089199
Recruiting
Not Applicable

The Effect of Cold Salt Water Foot Bath on the Development Of Chemotherapy-Induced Peripheral Neuropathy

Breast Cancer PatientsChemotherapy-induced Peripheral Neuropathy (CIPN)Paclitaxel-induced Peripheral Neuropathy
Tuba Eryiğit30 enrolled1 locationNCT06964802
Recruiting
Phase 2

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

TislelizumabPD-1 InhibitorKidney-sparing+2 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07233252
Recruiting

Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons

PaclitaxelACS (Acute Coronary Syndrome)CAD - Coronary Artery Disease+3 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)3,000 enrolled1 locationNCT07231835
Recruiting
Phase 2

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Triple-Negative Breast CancerNab-paclitaxel
Hebei Medical University Fourth Hospital414 enrolled1 locationNCT04159142
Recruiting
Phase 2

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Breast CancerTriple-Negative Breast CancerNab-paclitaxel
Hebei Medical University Fourth Hospital520 enrolled1 locationNCT04138719
Recruiting
Phase 2

Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Neoadjuvant TherapyPD-1 InhibitorUpper Tract Urothelial Carcinoma+1 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07126119
Recruiting
Phase 2

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Neoadjuvant TherapyTislelizumabPD-1 Inhibitor+3 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07125547
Recruiting
Not Applicable

A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel

Breast CancerReal Time Pressure ControllerAlbumin Paclitaxel+1 more
Tianjin Medical University Cancer Institute and Hospital118 enrolled1 locationNCT07019233
Recruiting
Not Applicable

Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy

Paclitaxel-induced Peripheral Neuropathy
Department of Medical Services Ministry of Public Health of Thailand36 enrolled1 locationNCT06763575
Recruiting

Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.

Breast CancerChemotherapeutic ToxicityPaclitaxel Adverse Reaction+3 more
Universitair Ziekenhuis Brussel40 enrolled2 locationsNCT06387901
Recruiting
Phase 3

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Ovarian CancerPaclitaxelRelapsed or Refractory+1 more
Chipscreen Biosciences, Ltd.454 enrolled1 locationNCT04921527
Recruiting
Phase 4

Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients

Breast CancerChemotherapyAlpha Lipoic Acid+2 more
Ain Shams University92 enrolled1 locationNCT06406127
Recruiting

European All-comers' Multicentric Prospective REGISTRY on LUMINOR© Drug Eluting Balloon in the Superficial Femoral Artery and Popliteal Artery With 5 Years Follow-up.

Peripheral Arterial DiseasePaclitaxelAngioplasty+2 more
iVascular S.L.U.500 enrolled15 locationsNCT04743180
Recruiting

Inter-ethnic differences in tolerance of anti-cancer drugs in non-small cell lung cancer patients

tolerance of palliative chemotherapy with carboplatin and paclitaxel in advanced non-small cell lung cancer patients
Sydney Cancer Centre120 enrolled1 locationACTRN12611000013965